title: Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases.
abstract: There are three main mechanisms of neuronal cell death which may act separately or cooperatively to cause neurodegeneration. This lethal triplet of metabolic compromise, excitotoxicity, and oxidative stress causes neuronal cell death that is both necrotic and apoptotic in nature. Aspects of each of these three mechanisms are believed to play a role in the neurodegeneration that occurs in both Parkinson's and Huntington's diseases. Strategies to rescue or protect injured neurons usually involve promoting neuronal growth and function or interfering with neurotoxic processes. Considerable research has been done on testing a large array of neuroprotective agents using animal models which mimic these disorders. Some of these approaches have progressed to the clinical arena. Here, we review neuroprotective strategies which have been found to successfully ameliorate the neurodegeneration associated with Parkinson's and Huntington's diseases. First, we will give an overview of the mechanisms of cell death and the background of Parkinson's and Huntington's diseases. Then we will elaborate on a range of neuroprotective strategies, including neurotrophic factors, anti-excitotoxins, antioxidants, bioenergetic supplements, anti-apoptotics, immunosuppressants, and cell transplantation techniques. Most of these approaches hold promise as potential therapies in the treatment of these disorders.
authors.affiliation: Research Centre for Developmental Medicine and Biology, School of Medicine, University of Auckland, New Zealand. t.alexi@auckland.ac.nz
authors.forename: T
authors.initials: T
authors.lastname: Alexi
authors.forename: C V
authors.initials: CV
authors.lastname: Borlongan
authors.forename: R L
authors.initials: RL
authors.lastname: Faull
authors.forename: C E
authors.initials: CE
authors.lastname: Williams
authors.forename: R G
authors.initials: RG
authors.lastname: Clark
authors.forename: P D
authors.initials: PD
authors.lastname: Gluckman
authors.forename: P E
authors.initials: PE
authors.lastname: Hughes
mesh_terms: D000818:Animals; D001479:Basal Ganglia / Q000187:drug effects / Q000473:pathology*; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy* / Q000473:pathology*; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000473:pathology*
chemical_list: D018696:Neuroprotective Agents